Introduction
The traditional preparative regimens used in unrelated donor (URD) hematopoietic SCT (HSCT) are myeloablative. The justifications for high-intensity regimens include advanced disease in many patients and the higher probability of graft failure compared with patients receiving related donor hematopoietic SCT. 1 CY combined with TBI (Cy/TBI) is the most common myeloablative regimen used in URD transplantation. The combination of the two agents provides the most effective immunosuppression allowing both engraftment and tolerance required for URD while also maximizing anti-tumor activity. In the early 1980s, BU was introduced in combination with CY (BuCy) as an alternative to Cy/TBI for myeloablation in sibling donor transplantation. The goals of this new preparative regimen were to reduce toxicity, improve outcome and provide an alternative for patients receiving prior radiation who would not be suitable candidates for TBI. 2, 3 Controversy exists as to the relative merits of BuCy and Cy/TBI regimens. Several randomized studies, as well as retrospective registry data in sibling donor transplants comparing the two types of preparative regimens report conflicting results concerning outcomes and toxicities. [4] [5] [6] [7] Although TBI-based regimens are widely used in URD transplantation, emerging data from several single institution trials report excellent outcome of BU-based regimens in leukemia patients. 3, 8, 9 However, there are no reports comparing outcomes between TBI-based and the BU-based regimens in URD transplants. The objective of this report is to compare clinical outcomes and toxicities of patients who received Cy/TBI regimens with those receiving BuCy regimens for URD transplantation in patients with acute myeloid leukemia, chronic myeloid leukemia and myelodysplasia.
Patients and methods

Data sources
The CIBMTR is a working group of more than 500 transplant centers worldwide that voluntarily contribute data on allogeneic and autologous transplants. Detailed demographic, disease and transplant characteristics and outcome data are collected on a sample of registered patients including all URD transplants facilitated by the National Marrow Donor Program (NMDP) in the US. Observational studies conducted by the CIBMTR are carried out with a waiver of informed consent and in compliance with HIPAA regulations as determined by the Institutional Review Board and the Privacy Officer of the Medical College of Wisconsin.
Patients
The study population included unrelated bone marrow transplant patients reported to the NMDP between 1991 and1999, who met the following criteria: (a) recipients of a T-cell-replete bone marrow transplant; (b) patients with the diagnosis of AML, CML and MDS; (c) patients who received a BuCy or Cy/TBI preparative regimen with TBI dose ranging from 10 to 15 Gy. Patients were excluded from this study if (a) they had received reduced-intensity preparative regimens; or (b) TBI doses in preparative regimens that were lower than 10 Gy or over 15 Gy; or (c) they had received a T-depleted marrow graft or ATG was given for in vivo T-cell depletion. There were 2089 patients selected according to the above criteria. Surviving recipients were then retrospectively contacted and provided informed consent for participation in the NMDP research program. The NMDP institutional review board waived consent for patients who died before consent was solicited. To address the potential bias introduced by the exclusion of non-consenting surviving patients, a corrective action plan modeling process that randomly excluded the same percentage of deceased patients using a weighted randomized scheme was used to adjust for over sampling of dead patients in the consented cohort. 10 After the corrective action plan model was applied, a total of 1804 (86.4%) patients remained. We further excluded 211 patients from the study because of missing key variables that could not be retrieved from the database or from the centers. Our final population, which included 1593 cases with AML, CML and MDS, was used in the univariate and multivariate analysis; these eligible cases came from 82 NMDP reporting centers.
The effect of transplant center on OS was tested using a score test for homogeneity and was found to be statistically significant. No significant interactions between center and the other main effects were found using a significance level of 1% (Po0.01). All multivariable analyses were stratified on centers to adjust for the center effect when determining whether outcomes were different depending on conditioning regimens.
HLA matching of donor and recipients Allele typing for HLA-A, -B, -C and DRB1 was available for most donors and recipients in our final population. Using previously defined matching criteria, well matched was defined as no known disparity at HLA-A, -B, -C and DRB1, partially matched as one known locus or a likely locus mismatch with their donors and mismatched as X2 locus disparity.
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Data collection
Outcomes for recipients were reported to the NMDP Coordinating Center by the transplant centers on standardized NMDP case report forms submitted at the time of transplantation (baseline), at 100 days, 6 months and annually thereafter. Acute GVHD was reported according to the consensus criteria for each organ stage. 12 The overall follow-up was 95%; patient follow-up at 1 year was 100%, at 3 years 99.33% and at 5 years 98.50%. The occurrence of organ toxicities, relevant clinical and laboratory data were captured on the case report forms, including specific organ toxicities such as veno-occlusive disease (VOD) of the liver, and interstitial pneumonitis (IPN).
Endpoints
The primary endpoints studied were TRM, relapse, diseasefree survival (DFS), OS, primary neutrophil and platelet engraftment. TRM was defined as death during a continuous complete remission. Relapse was defined as clinical or hematologic recurrence. Owing to the timing of the study period, our definition of relapse for CML patients was based on hematologic relapse. For analysis of DFS, failures were relapse or death from any cause; patients alive and in complete remission were censored at time of last follow-up. For analysis of OS, failure was death from any cause; surviving patients were censored at the date of last contact. Neutrophil and platelet engraftment were assessed in patients who survived at least 21 days post transplant. Time to neutrophil engraftment was defined as the time to achieve a sustained ANC of X500 cells/mL for 3 consecutive days. Time to platelet engraftment was defined as time to achieve a platelet count of 20 000/mL, evaluable at 7 days from the last platelet transfusion.
Disease stage was defined as follows: early diseases were AML in CR1, CML-CP1 and MDS of RA and RARS subtype; intermediate diseases were AML CR 41 or 1st relapse, CML-2nd chronic phase or accelerated phase; advanced diseases were AML with primary induction failure or X2nd relapse, CML-blast phase, MDS of RAEB-1 or RAEB-2 subtype and CMML. The growth factor variable was defined as whether a growth factor was initiated on day -1 to day 7 post transplant to promote engraftment.
Statistical analysis
Patient-, disease-and transplant-related variables were compared between patients who received BuCy, Cy/TBI standard-dose and Cy/TBI high-dose conditioning groups using the w 2 statistic for categorical and the Kruskal-Wallis test for continuous variables. The BuCy group included those patients who received BU (usually 16 mg/kg) and CY (usually 120-200 mg/kg). The BuCy-2 and BuCy-4 regimen could not be distinguished with the available data, as it did not specify the exact CY dose in all cases. Dose adjustment by weight is not reported, nor is the use of BU levels to direct dosing. In addition the data set did not capture whether any of the patients received intravenous (IV) BU. However, as the approval for IV BU did not occur until March of 1999, its influence was negligible.
Owing to large variations of the dose of radiation therapy used, a proportional hazards regression model using a forward selection was used on several TBI categories to see whether a breakpoint that had an impact on survival could be defined. This step was repeated for various TBI categories by 100 s by 50 s and by 25 s cGy. By this method, only 1000-1200 cGy entered into the survival model. This was used as the breakpoint for the dichotomous choice of standard-dose (1000-1200 cGy) and highdose (1320-1500 cGy) TBI.
Univariate probabilities of DFS and OS were calculated using the Kaplan-Meier estimator. 13 The log-rank test was used for comparing survival curves. Probabilities of TRM, relapse, neutrophil engraftment, platelet engraftment, acute GVHD, chronic GVHD, VOD and IPN were calculated using cumulative incidence estimates. Apart from TRM, the cumulative incidence calculated for the aforementioned outcomes treated death as a competing risk.
14 Relapse was treated as a competing risk for TRM. The cumulative incidence for chronic GVHD was only considered in patients who survived for at least 80 days.
In the multivariate analysis, proportional hazards regression models were used to investigate the effects of different conditioning regimens (BuCy, standard-dose Cy/TBI and high-dose Cy/TBI) on clinical endpoints while controlling for effects of the other potentially confounding factors. Main effects were considered significant if the corresponding P-values were smaller than 5%; interactions and proportional hazard assumptions were tested at 1%. The main effect being tested (BuCy, standard-dose Cy/TBI and high-dose Cy/TBI) was forced into each model in a stepwise selection procedure, regardless of its statistical significance for outcome. The following variables were considered as possible confounders and included in the regression model if they showed a statistically significant association with the primary outcome of interest: HLA match status, disease and disease stage, recipient and donor age, gender and CMV status, Karnofsky score at transplant, interval from diagnosis to transplant and year of transplantation. All computations were performed using the statistical package SAS version 9.1. 
Results
Demographics and univariate analysis
Engraftment and GVHD
The cumulative incidence of neutrophil and platelet engraftment is shown in Table 2 . By day þ 28 post BMT, the cumulative incidence of neutrophil engraftment was 88% (95% CI, 84-91) in the standard-dose Cy/TBI group, compared with 81% (95% CI, 78-84) in the high-dose Cy/ TBI and 80% (95% CI, 75-84) in the BuCy patients (P ¼ 0.001). The multivariate analysis also confirmed an advantage for neutrophil engraftment in the standard-dose Cy/TBI compared with either the BuCy or high-dose Cy/ TBI group (Po0.001) ( Table 3) .
The cumulative incidence of platelet engraftment was also higher in the standard-dose Cy/TBI group (Table 2) . On day þ 30, 49% (95% CI, 43-54) of patients in the standard-dose Cy/TBI group had evidence of platelet engraftment (420 000/mL ) compared with 29% (95% CI, [26] [27] [28] [29] [30] [31] [32] [33] in the high-dose Cy/TBI group and 38% (95% CI, 33-44) in the BuCy group (Po0.001). This advantage in platelet engraftment in the standard-dose Cy/TBI group was also significant at day 100 (P ¼ 0.002) and at 1 year (P ¼ 0.002).
The cumulative incidence of grades II-IV aGVHD (Table 2) shows a statistically significant difference between the regimens. However, on multivariate analysis there was no difference in the incidence of aGVHD between the three groups (P ¼ 0.96) ( Table 3 ). The cumulative incidence of grades III-IV aGVHD (Table 2) shows no significant difference between the regimens; however, the multivariate analysis showed that patients who received the high-dose 
CML (BP), MDS (RAEB, RAEB-T, CMML).
c Other GVHD prophylaxis were CY (n ¼ 1); ATG+corticosteroids (n ¼ 1); none (n ¼ 3). d Well matched was defined as no known disparity at HLA-A, -B, -C, DRB1, partially matched as one locus known or likely disparity with their donors and mismatched as X2 locus disparity. e Growth factor, G-CSF or GM-CSF, was delivered to promote engraftment. This was initiated between day À1 and day 7. Cy/TBI regimen had an increased risk of developing grades III-IV aGVHD (P ¼ 0.011).
At 6 months, the cumulative incidence of cGVHD was higher in patients receiving either standard-dose TBI or high-dose TBI regimens 35% (95% CI, 31-40) and 28% (95% CI, 25-31), respectively, compared with patients receiving BU regimens whose incidence of cGVHD was 23% (95% CI, 18-28) (P ¼ 0.001) ( Table 2) . At 1 year there continued to be a lower incidence of cGVHD in the BU group compared with either TBI groups but these differences did not achieve statistical significance (P ¼ 0.07).
OS, DFS, TRM and relapse
At 5 years the adjusted OS for the BuCy, standard-dose Cy/TBI and high-dose Cy/TBI was 35% (95% CI, 30-40), 32% (95% CI, 28-36) and 33% (95% CI, 30-36), respectively (P ¼ 0.779) (Figure 1 ). In the multivariate analysis for OS, there was no difference found in OS regardless of the preparative regimen used (P ¼ 0.236) ( Table 3 ). In the multivariate analysis there was also no difference in DFS between the groups (P ¼ 0.464).
The cumulative incidence of TRM and relapse is also shown in Table 2 . At 1 year, the cumulative incidence of TRM was similar among all three groups; 48% (95% CI, 43-54) in the BuCy group, 43% (95% CI, 39-48) in the standard-dose Cy/TBI group and 47% (95% CI, 43-50) in the high-dose Cy/TBI group (P ¼ 0.37). In the multivariate analysis there was no difference in the relative risk of TRM between the three groups (P ¼ 0.384) ( Table 3) .
In the univariate analysis the cumulative incidence of relapse was significantly higher at 1 year in the high-dose Cy/TBI group compared with the BuCy group or the standard-dose Cy/TBI group (Po0.001). However, in the multivariate analysis there was no difference in the relative risk of relapse between the three groups (P ¼ 0.155) ( Table 3) .
Regimen-related toxicity
The incidence of VOD using Seattle criteria 15 at day 100 was higher in patients who received the BuCy regimen-21% (95% CI, 16-26) compared with patients who received either standard-dose Cy/TBI 13% (95% CI, 10-16) or high-dose Cy/TBI 15% (95% CI, 13-18) (P ¼ 0.02). The development of IPN at day 100 was similar between the three groups: 20% (95% CI, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the BuCy group, 22% (95% CI, [18] [19] [20] [21] [22] [23] [24] [25] [26] in the standard-dose Cy/TBI group and 21% (95% CI, [19] [20] [21] [22] [23] [24] in the high-dose Cy/TBI group (P ¼ 0.91). These outcomes were not assessed in multivariate analysis.
Discussion
Historically, TBI has been the main modality for providing both tumoricidal and immunosuppressive effects to a Point-wise P-value unless otherwise noted. b Probabilities of disease-free survival OS were calculated using the Kaplan-Meier product limit estimate. Probabilities of engraftment, relapse, mortality, IPN, GVHD, VOD and treatment-related were calculated using the cumulative incidence.
facilitate engraftment of donor cells. 16, 17 Since the initial introduction of the BU and CY combination (BuCy-4) as a preparative regimen for leukemias in the mid-1980s, there have been increasing reports of its efficacy. 18 Modification of this regimen with the reduction of CY to 60 mg/kg/day for 2 days (BuCy-2) was found to be equally efficacious with apparent reduction of toxicity. 19, 20 Although there were no prospective trials comparing BuCy-2 and BuCy-4, many centers adopted BuCy-2 as standard for this combination. In this study, we compared the outcome of 1593 patients with myeloid disorders, AML, CML and myelodysplasia who received URD transplantation facilitated by the NMDP. There was no statistical differences noted in OS, DFS, TRM and relapse between patients who received BuCy or the TBI-based regimens.
Presently, five prospective randomized trials have compared TBI-based and BuCy regimens in recipients of sibling donor transplantation. [4] [5] [6] 21, 22 Most included patients with various stages of acute and chronic myeloid leukemia. In the two studies of patients in chronic phase CML, the treatment-related mortality, OS and DFSs of patients who received TBI and BuCy were similar. 6, 22 The remaining three studies included patients with early and advanced stages of disease. 4, 5, 21 Two studies showed a significant survival advantage for patients who received TBI regimens; one in AML in CR1, 4 and one in advanced disease. 5 In the French multicenter randomized trial comparing BuCy-2 with a TBI-based regimen in matched sibling transplantation for patients with AML in first remission, there was a significantly higher relapse rate in patients who received the BuCy-2 regimen, resulting in poorer OS and DFS. 4 There was also a higher relapse in patients who received BuCy for AML in first remission in a retrospective review from the IBMTR. 23 In this study in spite of the higher relapse rate the survival was equivalent. The higher relapse in both these studies, which included sibling transplants, may not be directly comparable to our study that only focused on unrelated transplants. In support of our study findings, a published meta-analysis suggested equivalent survival between the regimens. 24 In addition, a combined long-term follow-up of four of the previously published randomized trials, patients with CML and AML undergoing HLAidentical sibling transplantation had equivalent survival whether they received Cy/TBI or BuCy regimen. 25 The risk of developing grades III-IV aGVHD was higher in patients who received the high-dose TBI-based regimens compared with patients who received either the standarddose TBI or BuCy regimen. This higher risk of severe acute GVHD in patients who received higher doses of TBI may be related to the increased intensity of the preparative regimen. Preparative regimens that cause more tissue damage (higher intensity regimens) may enhance the risk of GVHD. 26, 27 It is possible that different preparative regimens, for example BU-based regimens, may attenuate tissue injury, thus lessening the risk of aGVHD. In the univariate analysis, the cumulative incidence of cGVHD was higher for Cy/TBI regimens at 6 months but only showed a trend at 1 year and 2 years with the incidence of 39-48%. This was lower than B70% observed in the prospective clinical trial comparing tacrolimus and cyclosporine in URD transplantation. 28 The difference of cGVHD incidence is most likely because of lower reporting sensitivity of registry data in patients with limited chronic GVHD compared with prospective data captured in real time.
Neutrophil engraftment at days 28 and 60 was higher in patients who received standard-dose Cy/TBI compared with patients who received either the BuCy or high-dose Cy/TBI regimens. This was statistically significant in both the univariate and multivariate analysis. Previous studies from the NMDP with CML patients indicated that the rate of neutrophil engraftment was improved in patients who received TBI-based regimens. 11 The reason was thought to be due to the greater immunosuppressive property of TBIbased regimens compared with BU-containing regimens.
However, the patients who received the high-dose TBIbased regimens in our study had a lower incidence of neutrophil engraftment compared with patients who received standard-dose TBI. Several differences in the characteristics of patients who received the high-dose Cy/TBI may account for the differences seen in this study. Patients receiving the high-dose Cy/TBI regimens had a greater likelihood of receiving an HLA-mismatched transplant and had advanced disease at the time of transplantation; both of these characteristics could potentially impede the recovery of neutrophils. Furthermore, other significant covariates that influenced neutrophil recovery in the multivariate analysis were HLA match status, Karnofsky score and total nucleated cell dose; the latter was higher in patients receiving BuCy regimen. Attainment of the desired cell dose in marrow harvest from a URD cannot consistently be achieved because of weight discrepancy and technical skill of the operators. Peripheral blood stem cell harvest is probably less operator-dependent and weight discrepancy is less of an issue, thus the issue of neutrophil engraftment might be more consistent. This is being addressed by the recently completed BMTCTN trial comparing marrow and peripheral blood SCT. It is also possible that the use of targeted blood levels of BU and IV formulation of BU might improve tumor cytoreduction in patients with advanced disease and enhance engraftment. [29] [30] [31] In this study, the relative risk of IPN was similar in all three groups. This finding is similar to previously reported studies on the risk of IPN after transplant. 32 The pathogenetic mechanism of IPN in the allogeneic transplant setting may not be directly related to the toxicity of any particular components of the conditioning regimens. Immunologic mechanisms may play a larger role in the development of IPN, thus overriding the impact of the preparative regimen on this complication. 33 The risk of VOD was higher in patients who received BuCy, compared with either Cy/TBI regimens in our study. The association of the preparative regimen and the risks of VOD were inconclusive in three randomized studies. One reported a significantly higher incidence of VOD in patients who received a BU-based regimen; 5,32 the other two studies did not find a difference in the risk of VOD between those who received a TBI-based regimen or BU-based regimen. 6, 7, 22 The risk of VOD might be minimized by strategies such as the use of ursodiol as a protective agent, 34 therapeutic monitoring of BU and using pharmacokinetic parameters 35, 36 or using a targeted steady-state plasma level of BU at 800-900 mg/ml. 30 More recently, the introduction of the IV formulation of BU may also decrease the risk of hepatic VOD. 37 Despite our best effort to delineate the interaction and influence of confounding factors in this large cohort of patients, some practical questions remain unanswered. For instance, these findings do not take into account several changes in the practice of unrelated transplantation and therefore caution must be used in generalization of these results. Certainly, current improvement of clinical practice that includes new microbial agents, antibodies to modify immune response, GVHD prophylactic regimens, selection of donors based on allelic typing and stem cell source has improved the outcome of unrelated transplants. In addition, the number of PBSC transplants has increased dramatically and PBSC now represents the major source of stem cells in patients undergoing unrelated transplantation. It is unclear whether the same observation in marrow transplant recipients as in this study would be true in the recipients of a PBSC transplant. This study does not delineate the role of intravenous BU, which is increasingly used in current practice. IV preparations of BU can potentially decrease the risk of VOD by avoiding the first pass effect on the liver. IV BU was approved by the FDA for use in 1999 and therefore not available for the majority of patients in this study. Finally, CML was the most common myeloid neoplasm in this study, but transplantation is now used far less since the introduction of tyrosine kinase inhibitors as frontline therapy for this disease.
In this large cohort analysis of CIBMTR registry data, we conclude that Cy/TBI and BuCy regimens result in similar clinical outcomes in URD transplant recipients with myeloid malignancies. Whether one regimen is superior in some subsets of URD transplant recipients is uncertain and will need further prospective study. Other prognostic variables might have a larger influence on survival than the preparative regimens described in this report.
